SCHEMBL21943007

SCHEMBL21943007

Cc1ccc(Oc2cc(-c3cccnc3)nc3[nH]ccc23)cc1C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIKFYVE Q9Y2I7 5/20 0.61
▸ KDR P35968 5/20 0.55
▸ MAPK14 Q16539 4/20 0.55
▸ CSF1R P07333 3/20 0.55
▸ KIT P10721 3/20 0.55
▸ BRAF P15056 2/20 0.52
▸ TNNI3K Q59H18 1/20 0.52
▸ MAPT P10636 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ LCK P06239 4/20 0.47
▸ SRC P12931 1/20 0.47
▸ BTK Q06187 1/20 0.46
▸ MET P08581 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ BCR P11274 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ SCN8A Q9UQD0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943684 0.92 KDR (0.51) PIKFYVEKDRMAPK14CSF1RKIT
SCHEMBL21943014 0.88 PIKFYVE (0.65) PIKFYVEKDRMAPK14CSF1RKIT
SCHEMBL21943532 0.87 PIKFYVE (0.68) PIKFYVEKDRMAPK14CSF1RKIT
SCHEMBL21944047 0.86 PIKFYVE (0.67) PIKFYVEKDRMAPK14CSF1RBRAF
SCHEMBL21943013 0.86 MAPK14 (0.54) PIKFYVEKDRMAPK14CSF1RKIT
SCHEMBL21943016 0.85 PIKFYVE (0.70) PIKFYVEKDRMAPK14CSF1RKIT
SCHEMBL21943516 0.84 PIKFYVE (0.75) PIKFYVEKDRMAPK14CSF1RKIT
SCHEMBL22025019 0.80 PIKFYVE (0.65) PIKFYVEKDRMAPK14CSF1RKIT
SCHEMBL21943068 0.80 PIKFYVE (0.54) PIKFYVEKDRMAPK14BRAFTNNI3K
SCHEMBL21943533 0.79 KDR (0.58) PIKFYVEKDRMAPK14CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof XIAMEN UNIVERSITY (CN) 2022-05-03 — — US disclosed
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP4A11, CYP2D6, CYP3A43 PIKFYVE 2706/4885KDR 2067/4885MAPK14 926/4885
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof CYP4A11, CYP2D6, CYP3A43 PIKFYVE 2706/4885KDR 2067/4885MAPK14 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback